The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients

(2015) Mohsen S. Elalfy et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Cross-Talk between Available Guidelines for the Management of Patients with Beta-Thalassemia Major

(2013) Khaled M. Musallam et al.   ACTA HAEMATOLOGICA

Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand

(2013) Vip Viprakasit et al.   AMERICAN JOURNAL OF HEMATOLOGY

Iron chelation therapy in the management of transfusion-related cardiac iron overload

(2012) Juliano Lara Fernandes   TRANSFUSION

Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications

(2011) Kallistheni Farmaki et al.   BLOOD CELLS MOLECULES AND DISEASES

Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies

(2011) Ersi Voskaridou et al.   BRITISH JOURNAL OF HAEMATOLOGY

Combining two orally active iron chelators for thalassemia

(2010) Vasilios Berdoukas et al.   ANNALS OF HEMATOLOGY

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

(2009) M. D. Cappellini et al.   HAEMATOLOGICA

Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone

(2009) Maria D. Cappellini et al.   HEMOGLOBIN

Iron Overload: Consequences, Assessment, and Monitoring

(2009) Ali T. Taher et al.   HEMOGLOBIN